Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 174

1.

Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.

Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D.

Ann Neurol. 2012 Aug;72(2):234-40. doi: 10.1002/ana.23591.

PMID:
22926855
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M.

Lancet. 1999 Mar 20;353(9157):964-9.

PMID:
10459905
[PubMed - indexed for MEDLINE]
3.

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.

Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH.

Brain. 2008 Mar;131(Pt 3):808-17. doi: 10.1093/brain/awm329. Epub 2008 Jan 29.

PMID:
18234696
[PubMed - indexed for MEDLINE]
Free Article
4.

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.

Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ.

Neurology. 2011 Oct 25;77(17):1611-8. doi: 10.1212/WNL.0b013e3182343274.

PMID:
22025459
[PubMed - indexed for MEDLINE]
5.

Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.

van Walderveen MA, Lycklama A Nijeholt GJ, Adèr HJ, Jongen PJ, Polman CH, Castelijns JA, Barkhof F.

Arch Neurol. 2001 Jan;58(1):76-81.

PMID:
11176939
[PubMed - indexed for MEDLINE]
6.

Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.

Bakshi R, Neema M, Healy BC, Liptak Z, Betensky RA, Buckle GJ, Gauthier SA, Stankiewicz J, Meier D, Egorova S, Arora A, Guss ZD, Glanz B, Khoury SJ, Guttmann CR, Weiner HL.

Arch Neurol. 2008 Nov;65(11):1449-53. doi: 10.1001/archneur.65.11.1449.

PMID:
19001162
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

MRI as an outcome in multiple sclerosis clinical trials.

Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC.

Neurology. 2009 Feb 24;72(8):705-11. doi: 10.1212/01.wnl.0000336916.38629.43. Epub 2008 Dec 10.

PMID:
19073945
[PubMed - indexed for MEDLINE]
8.

Brain atrophy and lesion load predict long term disability in multiple sclerosis.

Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, Chard DT, Matthews L, Palace J, Giorgio A, De Stefano N, Eisele P, Gass A, Polman CH, Uitdehaag BM, Messina MJ, Comi G, Filippi M, Barkhof F, Vrenken H; MAGNIMS Study Group.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1082-91. doi: 10.1136/jnnp-2012-304094. Epub 2013 Mar 23.

PMID:
23524331
[PubMed - indexed for MEDLINE]
9.

Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.

Teunissen CE, Sombekke M, van Winsen L, Killestein J, Barkhof F, Polman CH, Dijkstra CD, Blankenstein MA, Pratico D.

Mult Scler. 2012 Aug;18(8):1092-8. doi: 10.1177/1352458511433306. Epub 2012 Jun 13.

PMID:
22695538
[PubMed - indexed for MEDLINE]
10.

Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes.

Di Filippo M, Anderson VM, Altmann DR, Swanton JK, Plant GT, Thompson AJ, Miller DH.

J Neurol Neurosurg Psychiatry. 2010 Feb;81(2):204-8. doi: 10.1136/jnnp.2009.171769. Epub 2009 Sep 10.

PMID:
19744964
[PubMed - indexed for MEDLINE]
11.

A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.

Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, Gallo P, Filippi M.

Ann Neurol. 2010 Mar;67(3):376-83. doi: 10.1002/ana.21906.

PMID:
20373349
[PubMed - indexed for MEDLINE]
12.

Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.

Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.

Mult Scler. 2008 May;14(4):479-84. doi: 10.1177/1352458507085555.

PMID:
18562504
[PubMed - indexed for MEDLINE]
13.

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.

Paolillo A, Pozzilli C, Giugni E, Tomassini V, Gasperini C, Fiorelli M, Mainero C, Horsfield M, Galgani S, Bastianello S, Buttinelli C.

Eur J Neurol. 2002 Nov;9(6):645-55.

PMID:
12453081
[PubMed - indexed for MEDLINE]
14.

Vitamin D as an early predictor of multiple sclerosis activity and progression.

Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C.

JAMA Neurol. 2014 Mar;71(3):306-14. doi: 10.1001/jamaneurol.2013.5993.

PMID:
24445558
[PubMed - indexed for MEDLINE]
15.

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.

Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.

J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):773-80.

PMID:
11385012
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
[PubMed - indexed for MEDLINE]
17.

Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.

Pulizzi A, Rovaris M, Judica E, Sormani MP, Martinelli V, Comi G, Filippi M.

Arch Neurol. 2007 Aug;64(8):1163-8.

PMID:
17698707
[PubMed - indexed for MEDLINE]
18.

Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.

Løken-Amsrud KI, Holmøy T, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JS, Sandvik L, Torkildsen O, Wergeland S, Myhr KM.

Neurology. 2012 Jul 17;79(3):267-73. doi: 10.1212/WNL.0b013e31825fdf01. Epub 2012 Jun 13.

PMID:
22700809
[PubMed - indexed for MEDLINE]
19.

MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.

Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.

Mult Scler. 2002 Apr;8(2):119-23.

PMID:
11990868
[PubMed - indexed for MEDLINE]
20.

One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis.

Liguori M, Meier DS, Hildenbrand P, Healy BC, Chitnis T, Baruch NF, Khoury SJ, Weiner HL, Bakshi R, Barkhof F, Guttmann CR.

J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1125-31. doi: 10.1136/jnnp.2011.242115. Epub 2011 Mar 22.

PMID:
21429902
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk